PK/PD Expertise Shared on “Establishing Proper Preclinical-Clinical Strategy for IND Approval”
[Medical News· Ilgan Bosa] Woojung BIO, a preclinical testing specialist, and BXPLANT, a Clinical Development and Research Organization (CDRO) expert, announced on the 4th the successful completion of their seminar on “Preclinical/Clinical Development Strategies for Successful New Drug Development.”
This seminar was the second in a three-part series, focusing on the theme “Establishing Proper Preclinical-Clinical Strategy for IND Approval.” BXPLANT Co-CEO Heesun Kim, Dr. Kyoung Ryun Lee from the Korea Research Institute of Bioscience and Biotechnology, and Dr. Hyuna Lee from Samsung Bioepis served as speakers, sharing essential PK/PD expertise spanning from preclinical to clinical development.
A Woojung BIO representative stated, “Since establishing the Woojung BIO New Drug Cluster, we have continuously operated various programs to provide open innovation opportunities to biotech companies. The high level of interest shown in this seminar is gratifying, like a reward for our ongoing efforts.”
The representative added, “Woojung BIO will continue to operate evolving programs that build on our accumulated know-how to provide opportunities to more biotech companies.”
BXPLANT Co-CEO Minkeun Jo emphasized, “Clinical pharmacology, the theme of this seminar, is a crucial component of the new drug development process. In particular, the dosage prediction system utilizing PK/PD data is the best method to increase clinical success rates while minimizing time and costs.”
Upcoming Final Session
The final installment of this seminar series will be held on October 16, focusing on “Clinical Development Case Studies and Strategy Establishment.” The seminar is open to anyone seeking new drug development expertise, free of charge. Registration is available through the Woojung BIO and BXPLANT websites.
source : Woojung Bio & BXPLANT Successfully Conclude Clinical Development Strategy Seminar, Jeong-il Kim, Medical News· Ilgan Bosa, 2024.09.05., http://www.bosa.co.kr/news/articleView.html?idxno=2230580
